Magnetic resonance imaging contrast agents based on albumin nanoparticles

Abstract

Despite the potential safety hazards and side effects, small molecular magnetic resonance imaging (MRI) contrast agents have been generally used in clinical medical imaging. The development of stable, but low-toxicity and high-efficiency magnetic resonance contrast agents has been receiving continuous attention and research interest. With the deepening of studies, the combination of small molecular magnetic resonance contrast agents and albumin-based carriers is an effective strategy to obtain new MRI contrast agents with safety, low toxicity, high relaxation efficiency and targeting capability. In particular, the relaxivity values of some albumin-based nano-magnetic resonance contrast agents are greater than 100 mM⁻¹ s⁻¹, which is much higher than the relaxivity values of some small molecule MRI contrast agents. Therefore, herein, current research on albumin nanoparticle related MRI contrast agents is summarized, which is of great significance for clarifying the development direction of contrast agents.